Intrinsic targeting of inflammatory cells in the brain by polyamidoamine dendrimers upon subarachnoid administration

Nanomedicine

Volumn 5, Issue 9, 2010, Pages 1317-1329

  Dai, Hui ^a,b   Navath, Raghavendra S ^b,c   Balakrishnan, Bindu ^a   Guru, Bharath Raja ^b   Mishra, Manoj K ^c   Romero, Roberto ^b   Kannan, Rangaramanujam M ^b,c   Kannan, Sujatha ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^c Wayne State University   (United States)

Author keywords

cerebral palsy; microglia targeted drug delivery to the brain; neuroinflammation; PAMAM dendrimers

Indexed keywords

DENDRIMER; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; POLYAMIDOAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN; CEREBRAL PALSY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG STRUCTURE; DRUG SYNTHESIS; INFLAMMATORY CELL; MICROGLIA; NANOANALYSIS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANIMALS, NEWBORN; ASTROCYTES; BRAIN; CEREBRAL PALSY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DENDRIMERS; FEMALE; FLUORESCEIN-5-ISOTHIOCYANATE; MALE; MICROGLIA; RABBITS; SUBARACHNOID SPACE;

EID: 78650070100     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/nnm.10.89     Document Type: Article

References (44)

1. Svenson S, Tomalia DA: Dendrimers in biomedical applications-refections on the feld. Adv. Drug Delivery Rev. 57(15), 2106-2129 (2005).
2. Lee CC, Mackay JA, Frechet JMJ, Szoka FC: Designing dendrimers for biological applications. Nat. Biotechnol. 23, 1517-1526 (2005).
3. Menjoge AR, Kannan RM, Tomalia DA: Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov. Today. 15, 171-185 (2010).
4. Huang RQ, Qu YH, Ke WL et al.: Effcient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modifed polyamidoamine dendrimer. FASEB J. 21(4), 1117-1125 (2007).
5. Li SD, Huang L: Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 5(4), 496-504 (2008).
6. Barrett T, Ravizzini G, Choyke PL, Kobayashi H: Dendrimers in medical nanotechnology. IEEE Eng. Med. Biol. Mag. 28(1), 12-22 (2009).
7. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M: Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int. J. Pharm. 259, 143-160 (2003).
8. Kobayashi H, Brechbiel MW: Nano-sized MRI contrast agents with dendrimer cores. Adv. Drug Del. Rev. 57(15), 2271-2285 (2005).
9. Almutairi A, Rossin R, Shokeen M et al.: Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis. Proc. Natl Acad. Sci. USA 106(3), 685-690 (2009).
10. Kang H, DeLong R, Fisher MH, Juliano RL: Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm. Res. 22, 2099-2106 (2005). (Pubitemid 41821589)
11. Khan MK, Nigavekar SS, Minc LD et al.: In vivo biodistribution of dendrimers and dendrimer nanocomposites-implications for cancer imaging and therapy. Technol. Cancer. Res. Treat. 4(6), 603-613 (2005).
12. Longmire M, Choyke PL, Kobayashi H: Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine 3(5), 703-717 (2008).
13. Nigavekar SS, Sung LY, Llanes M et al.: 3H dendrimer nanoparticle organ/tumor distribution. Pharm. Res. 21(3), 476-483 (2004).
14. 125I-labelled polyamidoamine dendrimers in vivo. J. Control. Release 65, 133-148 (2000).
15. 3 integrins. Bioconjug. Chem. 18(4), 1148-1154 (2007).
16. Chandrasekar D, Sistla R, Ahmad FJ, Khar RK, Diwan PV: The development of folate-PAMAM dendrimer conjugates for targeted delivery of anti-arthritic drugs and their pharmacokinetics and biodistribution in arthritic rats. Biomaterials 28(3), 504-512 (2007).
17. Bennewitz MF, Saltzman WM: Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics 6(2), 323-336 (2009).
18. Yan Q, Matheson C, Sun J et al.: Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with TRK receptor expression. Exp. Neurol. 127, 23-36 (1994).
19. 11C-(R)-PK11195 and small-animal PET. J. Nucl. Med. 48(6), 946-954 (2007).
20. Saadani-Makki F, Kannan S, Lu X et al.: Intrauterine administration of endotoxin leads to motor defcits in a rabbit model: a link between prenatal infection and cerebral palsy. Am. J. Obstet. Gynecol. 199(6), 651-657 (2008).
21. Pardridge WM: Blood-brain barrier delivery. Drug. Discov. Today. 12(1-2), 54-61 (2007).
22. Allard E, Passirani C, Benoit JP: Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 30(12), 2302-2318 (2009).
23. Neeves KB, Sawyer AJ, Foley CP et al.: Dilation and degradation of the brain extracellular matrix enhances penetration of infused polymer nanoparticles. Brain Res. 1180, 121-132 (2007).
24. Perumal OP, Inapagolla R, Kannan S, Kannan RM: The effect of surface functionality on cellular traffcking of dendrimers. Biomaterials 29(24-25), 3469-3476 (2008).
25. Menjoge AR, Navath RS, Asad A et al.: Transport and biodistribution of dendrimers across human fetal membranes: implications for intravaginal administration of dendrimer-drug conjugates. Biomaterials 31(18), 5007-5021 (2010).
26. Navath RS, Menjoge AR, Wang B, Romero R, Kannan S, Kannan RM: Amino acid-functionalized dendrimers with heterobifunctional chemoselective peripheral groups for drug delivery applications. Biomacromolecules 11(6), 1544-1563 (2010).
27. Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 8, 57-69 (2007).
28. Nimmerjahn A, Kirchhoff F, Helmchen F: Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318 (2005). (Pubitemid 40746128)
29. Napoli I, Neumann H: Microglial clearance function in health and disease. Neuroscience 158, 1030-1038 (2009).
30. Stence N, Waite M, Dailey ME: Dynamics of microglial activation: a confocal time-lapse ana lysis in hippocampal slices. Glia. 33(3), 256-266 (2001).
31. Carbonell WS, Murase S, Horwitz AF et al.: Migration of perilesional microglia after focal brain injury and modulation by CC chemokine receptor 5: an in situ time-lapse confocal imaging study. Neurosci. 25(30), 7040-7047 (2005).
32. Brierley JB, Brown AW: The origin of lipid phagocytes in the central nervous system: I. The intrinsic microglia. Comp. Neuro. 211(4), 397-406 (1982).
33. Gehrmann J, Schoen SW, Kreutzberg GW: Lesion of the rat entorhinal cortex leads to a rapid microglial reaction in the dentate gyrus. A light and electron microscopical study. Acta Neuropathol (Berl). 82(6), 442-455 (1991).
34. Kigerl KA, Gensel JC, Ankeny DP et al.: Identifcation of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. Neurosci. 29(43), 13435-13444 (2009).
35. Husemann, J, Loike JD, Anankov R et al.: Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system. Glia. 40, 195-205 (2002).
36. Bell MD, Lopez-Gonzalez R, Lawson L et al.: Upregulation of the macrophage scavenger receptor in response to different forms of injury in the CNS. Neurocytol. 23, 605-613 (1994).
37. Grewal R P, Yoshida T, Finch CE et al.: Scavenger receptor mRNAs in rat brain microglia are induced by kainic acid lesioning and by cytokines. Neuro. Report. 8, 1077-1081 (1997).
38. Hutter E, Boridy S, Labrecque S et al.: Microglial response to gold nanoparticles. ACS Nano. 4(5), 2595-2606 (2010).
39. Pickard MR, Chari DM: Robust Uptake of magnetic nanoparticles (MNPs) by central nervous system (CNS) microglia: implications for particle uptake in mixed neural cell populations. Int. J. Mol. Sci. 11, 967-981 (2010).
40. Wang B, Navath RS, Romero R, Kannan S, Kannan R: Anti-infammatory and anti-oxidant activity of anionic dendrimer-N-acetyl cysteine conjugates in activated microglial cells. Int. J. Pharm. 377(1-2), 159-168 (2009).
41. Kalmar B, Kittel A, Lemmens R et al.: Cultured astrocytes react to LPS with increased cyclooxygenase activity and phagocytosis. Neurochem. Int. 38, 453-461 (2001).
42. Lee SC, Moore GR, Golenwsky CS et al.: Multiple sclerosis: a role for astroglia in active demyelination suggested by class II MHC expression and ultrastructural study. J. Neuropathol. Exp. Neurol. 49, 122-136 (1990).
43. Bechmann I, Nitsch R: Astrocytes and microglial cells incorporate degenerating fbers following entorhinal lesion: a light, confocal, and electron microscopical study using a phagocytosis-dependent labeling technique. Glia. 20, 145-154 (1997).
44. Nicholasa AP, McInnisa C, Gupta KB et al.: The fate of biodegradable microspheres injected into rat brain. Neurosci. Lett. 323, 85-88 (2002).